Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1882 1
1886 1
1945 1
1946 1
1947 2
1948 1
1949 1
1950 3
1951 2
1952 4
1953 3
1954 4
1955 3
1956 4
1957 4
1960 3
1961 2
1962 4
1964 1
1965 3
1967 1
1968 3
1969 3
1970 3
1971 3
1972 6
1973 3
1974 1
1975 3
1976 3
1978 1
1979 1
1982 1
1983 2
1985 2
1987 1
1988 5
1989 3
1990 4
1993 5
1994 3
1995 5
1996 1
1997 6
1998 6
1999 9
2000 5
2001 5
2002 5
2003 7
2004 8
2005 17
2006 14
2007 12
2008 30
2009 25
2010 34
2011 28
2012 35
2013 30
2014 33
2015 42
2016 36
2017 43
2018 39
2019 34
2020 50
2021 54
2022 35
2023 29
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

697 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; REGAIN Study Group. Howard JF Jr, et al. Among authors: o brien f. Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20. Lancet Neurol. 2017. PMID: 29066163 Clinical Trial.
Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.
Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Nowak RJ, Andersen H, Casasnovas C, de Bleecker JL, Vu TH, Mantegazza R, O'Brien FL, Wang JJ, Fujita KP, Howard JF Jr; Regain Study Group. Muppidi S, et al. Among authors: o brien fl. Muscle Nerve. 2019 Jul;60(1):14-24. doi: 10.1002/mus.26447. Epub 2019 Mar 8. Muscle Nerve. 2019. PMID: 30767274 Free PMC article.
Editorial. Tissue engineering.
O'Brien FJ, Harley BA. O'Brien FJ, et al. J Mech Behav Biomed Mater. 2012 Jul;11:1-2. doi: 10.1016/j.jmbbm.2012.04.020. J Mech Behav Biomed Mater. 2012. PMID: 22658149 No abstract available.
Editorial: Advanced Cell Culture Technologies to Boost Cell-Based Therapies.
Egger D, Boccaccini AR, Correa D, Kasper C, O'Brien FJ. Egger D, et al. Among authors: o brien fj. Front Bioeng Biotechnol. 2021 Jul 19;9:727298. doi: 10.3389/fbioe.2021.727298. eCollection 2021. Front Bioeng Biotechnol. 2021. PMID: 34350168 Free PMC article. No abstract available.
697 results